...
首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >DESIGN, SYNTHESIS OF BIOLOGICALLY ACTIVE HETEROCYCLES CONTAINING INDOL- THIAZOLYL- THIAZOLIDINONE DERIVATIVES
【24h】

DESIGN, SYNTHESIS OF BIOLOGICALLY ACTIVE HETEROCYCLES CONTAINING INDOL- THIAZOLYL- THIAZOLIDINONE DERIVATIVES

机译:包含吲哚-噻唑基-噻唑烷酮衍生物的生物活性杂环的设计,合成

获取原文

摘要

Objective: The present study envisage a novel series of thiazole, indole and thiazolidine derivatives, namely, N -((5-Substituted-2-phenyl-1 H -indol-3-yl)methylene)-4,5,6,7-tetrahydro-5,7,-dimethylbenzo [d]thiazole-2-amine (4a-c), 2-(5-substituted-2-phenyl-1 H -indol-3-yl)-3-(4,5,6,7- trimethylbenzo[d]thiazol-2-yl)-thiazolidin-4-one (5a-c) and 5-benzylidine-2-(5-substituted-2phenyl-1 H -indol-3yl)-3-(4,5,6,7-tetrahydro-5,5,7- trimethylbenzo[d]thiazol-2-yl) thiazolidin-4-one (6a-c). Methods: All the newly synthesized compounds were characterized by infrared, 1H, 13C nuclear magnetic resonance and mass spectral data and elemental analysis and evaluated for in vitro antimicrobial activity. Results: Novel compounds N -((5-Substituted-2-phenyl-1 H -indol-3-yl)methylene)-4,5,6,7-tetrahydro-5,7,-dimethylbenzo [d]thiazole-2-amine (4a-c), 2-(5-substituted-2-phenyl-1 H -indol-3-yl)-3-(4,5,6,7-trimethylbenzo[d]thiazol-2-yl)-thiazolidin-4-one (5a-c) and 5-benzylidine-2-(5-substituted- 2phenyl-1 H -indol-3yl)-3-(4,5,6,7-tetrahydro-5,5,7-trimethyl benzo[d]thiazol-2-yl)thiazolidin-4-one (6a-c) have been made and characterized using spectral and analytical data. The results of antibacterial and antifungal activities showed that some of the synthesized compounds exhibited promising activities. Conclusion: All the newly synthesized compounds were carried out by the broth microdilution method (NCCLS. 2002) in a DMF concentration of 500, 250, 125, and 62.5 μg/ml. Gentamycin and fluconazole are used as reference standards for antibacterial and antifungal activity, respectively. The final results revealed that compounds 4b, 5b, and 6b exhibited potent antimicrobial activity when compared to the standard drugs.
机译:目的:本研究设想了一系列新的噻唑,吲哚和噻唑烷衍生物,即N-((5-取代-2-苯基-1 H-吲哚-3-基)亚甲基)-4,5,6,7 -四氢-5,7,-二甲基苯并[d]噻唑-2-胺(4a-c),2-(5-取代-2-苯基-1 H-吲哚-3-基)-3-(4,5 ,6,7-三甲基苯并[d]噻唑-2-基)-噻唑烷-4-酮(5a-c)和5-苄基-2-(5-取代的2-苯基-1 H-吲哚-3基)-3- (4,5,6,7-四氢-5,5,7-三甲基苯并[d]噻唑-2-基)噻唑烷丁-4-酮(6a-c)。方法:通过红外,1H,13C核磁共振,质谱数据和元素分析对所有新合成的化合物进行表征,并评估其体外抗菌活性。结果:新化合物N-((5-取代-2-苯基-1 H-吲哚-3-基)亚甲基)-4,5,6,7-四氢-5,7,-二甲基苯并[d]噻唑-2 -胺(4a-c),2-(5-取代-2-苯基-1 H-吲哚-3-基)-3-(4,5,6,7-三甲基苯并[d]噻唑-2-基) -噻唑烷丁-4-酮(5a-c)和5-苄基-2-(5-取代的-2-苯基-1H-吲哚-3基)-3-(4,5,6,7-四氢-5,5,已经制备了7-三甲基苯并[d]噻唑-2-基)噻唑烷丁-4-酮(6a-c),并使用光谱和分析数据对其进行了表征。抗菌和抗真菌活性的结果表明,一些合成的化合物表现出有希望的活性。结论:所有新合成的化合物均通过肉汤微稀释法(NCCLS。2002)在DMF浓度分别为500、250、125和62.5μg/ ml的条件下进行。庆大霉素和氟康唑分别用作抗菌和抗真菌活性的参考标准。最终结果表明,与标准药物相比,化合物4b,5b和6b表现出强大的抗菌活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号